Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients

NACompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Sickle Cell Disease
Interventions
OTHER

Blood sampling - healthy volunteers

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

OTHER

Blood sampling - sickle cell patients arm - stable condition

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

OTHER

Blood sampling - sickle cell patients arm- exsanguinotransfusion needed

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.

OTHER

Blood sampling - sickle cell patients arm - vaso-occlusive crisis.

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

Trial Locations (1)

1020

CHU Brugmann Hospital, Brussels

All Listed Sponsors
lead

Brugmann University Hospital

OTHER

NCT02565082 - Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients | Biotech Hunter | Biotech Hunter